Natural Capsules

What does Natural Capsules do?

Natural Capsules Ltd is a micro-cap manufacturer of hard capsule shells in the Pharmaceuticals & Biotechnology industry, known for introducing vegetarian capsules in India and being the second-largest producer of gelatin capsules. As of March 2025, it reported net sales of 45 Cr and a net profit of 1 Cr.

Overview: <BR>Natural Capsules Ltd is a leading manufacturer of hard capsule shells in the Pharmaceuticals & Biotechnology industry, classified as a micro-cap company.<BR><BR>History: <BR>Natural Capsules Ltd was incorporated as a Public Limited Company in 1993. The company has established itself as a significant player in the market, introducing vegetarian capsules to India and becoming the second-largest manufacturer of gelatin capsules in the country. The latest quarterly results reported net sales and profit for March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 45 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 1 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 259 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 259.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.37 <BR>Return on Equity: 0.93% <BR>Price to Book: 1.11 <BR><BR>Contact Details: <BR>Address: Trident Towers 4th Floor No 23, 100Feet Road Jayanagar II Block Bangalore Karnataka : 560011 <BR>Tel: 91-080-26671571/26671573/26671581 <BR>Email: company.sec@naturalcapsules.com <BR>Website: http://www.naturalcapsules.com

Has Natural Capsules declared dividend?

Natural Capsules Ltd has declared a 10% dividend, amounting to 1 per share, with an ex-date of July 20, 2023. Despite the dividend declaration, the company has experienced negative total returns in the short to medium term, but has shown strong recovery over the longer 4 to 5-year periods.

Natural Capsules Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1 per share<BR>- Ex-date: 20 Jul 23<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -13.79%, with a dividend return of 0%, resulting in a total return of -13.79%.<BR><BR>Over the past year, the price return was -10.27%, with a dividend return of 0%, leading to a total return of -10.27%.<BR><BR>In the 2-year period, the price return was -26.91%, with a dividend return of 0.27%, culminating in a total return of -26.64%.<BR><BR>For the 3-year period, the price return was -44.67%, with a dividend return of 0.50%, resulting in a total return of -44.17%.<BR><BR>In the 4-year period, the price return was 63.49%, with a dividend return of 2.01%, leading to a total return of 65.5%.<BR><BR>Over the last 5 years, the price return was 432.19%, with a dividend return of 7.21%, resulting in a total return of 439.4%.<BR><BR>Overall, while Natural Capsules Ltd has declared a dividend, the recent total returns indicate a mixed performance, with significant declines in the short to medium term, but a strong recovery over the longer 4 to 5-year periods.

Who are the peers of the Natural Capsules?

Natural Capsules' peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Pharmaids Pharma, Alpa Laboratorie, Panch. Organics, Syschem (India), and Bafna Pharma. Natural Capsules has below-average management risk and a -20.72% return over the past year, significantly underperforming compared to its peers.

Peers: The peers of Natural Capsules are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Pharmaids Pharma, Alpa Laboratorie, Panch.Organics, Syschem (India), and Bafna Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Good management risk is found at Divi's Lab., Torrent Pharma, and the rest. Below Average management risk is noted for Natural Capsules, Pharmaids Pharma, Syschem (India), and Bafna Pharma, while Average management risk is seen at Alpa Laboratorie and Panch.Organics. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, Good for Natural Capsules, and Below Average for Divi's Lab., Torrent Pharma, Pharmaids Pharma, Alpa Laboratorie, Panch.Organics, and Syschem (India). Capital Structure is Excellent for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Alpa Laboratorie, Good for Torrent Pharma and Natural Capsules, and Below Average for Pharmaids Pharma, while Average is found at Syschem (India) and Bafna Pharma.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.69%, while Natural Capsules has the lowest at -20.72%. This indicates that Natural Capsules' performance is significantly below that of Divi's Lab. Additionally, the six-month return is negative for Natural Capsules, Torrent Pharma, Alpa Laboratorie, Panch.Organics, and Bafna Pharma.

What is the technical trend for Natural Capsules?

As of June 4, 2025, Natural Capsules show a neutral technical stance with mixed signals: mildly bullish weekly indicators contrast with bearish monthly trends.

As of 4 June 2025, the technical trend for Natural Capsules has changed from mildly bearish to sideways. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish. The weekly Bollinger Bands are bullish, contrasting with the monthly which is mildly bearish. Daily moving averages show a mildly bearish trend. The KST is mildly bullish on the weekly but bearish on the monthly, and Dow Theory supports a mildly bullish view on both weekly and monthly time frames. The OBV is bullish for both weekly and monthly periods. Overall, the current technical stance is neutral, with mixed signals across different indicators.

Who are in the management team of Natural Capsules?

As of March 2023, the management team of Natural Capsules includes Laxminarayan Moondra, Satyanarayan Mundra, C P Rangachar, Sunil L Mundra, Sushil Kumar Mundra, Jyothi Mundra, Pramod Kasat, Shilpa Burman, and Shirish Gundopant Belapure, who oversee the company's operations and strategic direction.

As of March 2023, the management team of Natural Capsules includes:<BR><BR>1. Laxminarayan Moondra - Whole-time Director<BR>2. Satyanarayan Mundra - Whole-time Director<BR>3. C P Rangachar - Chairman & Independent Director<BR>4. Sunil L Mundra - Managing Director<BR>5. Sushil Kumar Mundra - Director<BR>6. Jyothi Mundra - Director<BR>7. Pramod Kasat - Independent Director<BR>8. Shilpa Burman - Company Secretary & Compliance Officer<BR>9. Shirish Gundopant Belapure - Independent Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Who are the top shareholders of the Natural Capsules?

The top shareholders of Natural Capsules include Tajos Investments Private Limited with 12.12%, followed by Tarinika Management LLP at 3.22%, and individual investors holding a collective 33.09%. There are no mutual funds or foreign institutional investors currently involved.

The top shareholders of Natural Capsules are primarily the promoters, with Tajos Investments Private Limited holding the highest stake at 12.12%. In terms of public shareholders, Tarinika Management LLP is the largest, owning 3.22%. Additionally, individual investors collectively hold 33.09% of the company's shares. There are currently no mutual funds or foreign institutional investors (FIIs) holding shares in the company.

How big is Natural Capsules?

As of 24th July, Natural Capsules Ltd has a market capitalization of 226.00 Cr, with recent net sales of 169.20 Cr and a net profit of 0.62 Cr. Shareholder's funds are 232.94 Cr, and total assets are 419.35 Cr as of March 2025.

As of 24th July, Natural Capsules Ltd has a market capitalization of 226.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Natural Capsules reported Net Sales of 169.20 Cr and a Net Profit of 0.62 Cr.<BR><BR>As of March 2025, the company's Shareholder's Funds amounted to 232.94 Cr, while Total Assets were reported at 419.35 Cr.

How has been the historical performance of Natural Capsules?

Natural Capsules experienced fluctuating financial performance, with net sales increasing to 169.21 Cr in March 2025 but a decline in profitability, as profit after tax fell to 0.62 Cr. Total assets grew to 419.35 Cr, indicating growth in sales and assets despite challenges in profitability.

Answer:<BR>The historical performance of Natural Capsules shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Natural Capsules reported net sales of 169.21 Cr in March 2025, an increase from 155.42 Cr in March 2024, but a decrease from 172.37 Cr in March 2023. The total operating income followed a similar pattern, reaching 169.21 Cr in March 2025. Raw material costs rose to 86.88 Cr in March 2025 from 84.00 Cr in March 2024, while total expenditure increased to 151.69 Cr in March 2025. Operating profit (PBDIT) decreased to 18.22 Cr in March 2025 from 21.86 Cr in March 2024, leading to a profit before tax of 2.79 Cr in March 2025, down from 8.05 Cr the previous year. The profit after tax also fell to 0.62 Cr in March 2025 from 5.55 Cr in March 2024. Total assets grew to 419.35 Cr in March 2025, up from 376.53 Cr in March 2024, while total liabilities also increased to 419.35 Cr. Cash flow from operating activities showed a positive trend with 26.00 Cr in March 2025, compared to -8.00 Cr in March 2024. Overall, the company's financial performance reflects both growth in sales and assets, but challenges in profitability in the most recent year.

Is Natural Capsules overvalued or undervalued?

As of November 14, 2025, Natural Capsules is considered overvalued and risky, with concerning financial metrics such as a PE ratio of -16.93 and an EV to EBITDA of 37.39, significantly underperforming compared to competitors like Sun Pharma and Cipla, and reflecting a negative stock performance of -28.65% over the past year.

As of 14 November 2025, the valuation grade for Natural Capsules has moved from expensive to risky, indicating a significant shift in the company's perceived value. Based on the analysis, Natural Capsules is currently considered overvalued. The company displays a PE ratio of -16.93, an EV to EBITDA of 37.39, and a Price to Book Value of 0.87, which are concerning metrics compared to its peers.<BR><BR>In comparison to notable competitors, Sun Pharma has a PE ratio of 36.49 and an EV to EBITDA of 24.09, while Cipla maintains a more attractive PE ratio of 22.72 and an EV to EBITDA of 16.08. These ratios highlight that Natural Capsules is not only underperforming relative to its peers but also suggests a lack of investor confidence reflected in its negative stock performance over the past year, with a return of -28.65% compared to a 9.00% gain in the Sensex.

When is the next results date for Natural Capsules Ltd?

The next results date for Natural Capsules Ltd is 13 February 2026.

The next results date for Natural Capsules Ltd is scheduled for 13 February 2026.

Are Natural Capsules Ltd latest results good or bad?

Natural Capsules Ltd's latest results are concerning, showing a net loss of ₹6.99 crores for Q2 FY26, a significant decline from last year's profit, despite an 11.11% revenue increase. The company's operating margin is at -1.94%, and the stock has dropped 4.66% post-announcement, indicating serious financial challenges and a "STRONG SELL" rating.

Natural Capsules Ltd's latest results are concerning and indicate a significant decline in financial health. The company reported a net loss of ₹6.99 crores for Q2 FY26, which is a drastic increase in losses compared to the same quarter last year, where they had a positive net profit. Although revenue increased by 11.11% year-on-year to ₹45.80 crores, this growth is overshadowed by severe margin compression, leading to an operating margin of -1.94%, the lowest in seven quarters.<BR><BR>The stock price has reacted negatively, plummeting 4.66% to ₹195.50 following the results announcement, and it has experienced a year-to-date decline of 27.99%. The company's performance has significantly underperformed the broader market, with a Mojo Score of just 23 out of 100 and a "STRONG SELL" rating.<BR><BR>Overall, the results reflect a company struggling with operational inefficiencies and rising costs, which have led to a critical financial situation. The outlook appears bleak, with multiple red flags indicating that investors should approach with caution.

Should I buy, sell or hold Natural Capsules Ltd?

Why is Natural Capsules Ltd falling/rising?

As of 16-Mar, Natural Capsules Ltd's stock price is at Rs 145.25, down 2.52%, and nearing its 52-week low. The stock has significantly underperformed, with a year-to-date drop of 13.34% and a 63.76% decline over three years, while trading activity shows decreased investor interest.

As of 16-Mar, Natural Capsules Ltd's stock price is falling, currently at Rs 145.25, which reflects a decrease of Rs 3.75 or 2.52%. The stock has underperformed the sector by 1.4% today and is close to its 52-week low, being only 0.17% away from Rs 145. Additionally, the stock has shown a significant decline over various periods, including a year-to-date drop of 13.34% and a staggering 63.76% decrease over the past three years, while the benchmark Sensex has increased by 31.00% in the same timeframe.<BR><BR>Today's trading activity indicates a lack of investor interest, with delivery volume falling by 86.32% compared to the 5-day average. Furthermore, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a bearish trend. The combination of these factors contributes to the ongoing decline in the stock price of Natural Capsules Ltd.

Which are the latest news on Natural Capsules?